Please login to the form below

Not currently logged in
Email:
Password:

farletuzumab

This page shows the latest farletuzumab news and features for those working in and with pharma, biotech and healthcare.

Late-stage ovarian cancer

Late-stage ovarian cancer

Menarini Biotech's abagovomab and Morphotek/ Eisai's farletuzumab have both had disappointing results in late-stage clinical trials. ... Farletuzumab had also entered global phase III trials, in combination with carboplatin and a taxane, in patients with

Latest news

  • Eisai's farletuzumab fails ovarian cancer trial Eisai's farletuzumab fails ovarian cancer trial

    Eisai's farletuzumab fails ovarian cancer trial. Unable to improve progression-free survival. ... Morphotek remains committed to research to understand the potential role of farletuzumab in ovarian and other types of cancer.".

More from news
Approximately 1 fully matching, plus 1 partially matching documents found.

Latest Intelligence

  • Eisai: Bucking the trend with R&D growth Eisai: Bucking the trend with R&D growth

    The monoclonal antibody farletuzumab is in phase III trials for ovarian cancer, and has reached the phase II stage for non-small cell lung cancer, while lenvatinib is also in phase

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Makara Health

Independent healthcare communications agency with a passion to develop inspirational ideas that create sustained and positive change. Whether it is...

Latest intelligence

The gene therapy revolution
Gene therapies are bringing new hope for many people with diseases caused by genetic disorders...
PM Society Digital Awards – the power of together
Our chief executive, Emma Statham, writes about the value of awards and the power of together....
Seduction_feature_image_thumb.jpg
Seduce anyone in four simple steps
You know the health of the global economy is dependent on our ability to seduce one another – don’t you? And you know that we need to be able to...

Infographics